Baseline susceptibility of primary HIV-2 to entry inhibitors

Antiviral Therapy

Volumn 17, Issue 3, 2012, Pages 565-570

  Borrego, Pedro ^a,b   Calado, Rita ^a,b   Marcelino, José M ^c   Bártolo, Inês ^a,b   Rocha, Cheila ^a,b   Cavaco Silva, Patrícia ^b   Doroana, Manuela ^d   Antunes, Francisco ^d   Maltez, Fernando ^e   Caixas, Umbelina ^f   Barroso, Helena ^a,b   Taveira, Nuno ^a,b,g  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^b INSTITUTO SUPERIOR DE CIÊNCIAS DA SAÚDE EGAS MONIZ   (Portugal)

^c INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^d HOSPITAL DE SANTA MARIA   (Portugal)

^e HOSPITAL CURRY CABRAL   (Portugal)

^f HOSPITAL DE SÃO JOSÉ   (Portugal)

^g INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; ENFUVIRTIDE; MARAVIROC; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; PLERIXAFOR; TIFUVIRTIDE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DOSE RESPONSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SYMPTOMATOLOGY; VIRUS ENTRY; VIRUS REPLICATION;

AMIDES; ANTI-HIV AGENTS; CYCLOHEXANES; FEMALE; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HIV-2; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MICROBIAL SENSITIVITY TESTS; PEPTIDE FRAGMENTS; QUATERNARY AMMONIUM COMPOUNDS; RECEPTORS, CCR5; TRIAZOLES;

EID: 84861694354     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1996     Document Type: Article

References (20)

1. Ntemgwa ML, d'Aquin Toni T, Brenner BG, Camacho RJ, Wainberg MA. Antiretroviral drug resistance in human immunodeficiency virus type 2. Antimicrob Agents Chemother 2009; 53:3611-3619.
2. Shi Y, Brandin E, Vincic E, et al. Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation. J Gen Virol 2005; 86:3385-3396. (Pubitemid 41685173)
3. Reeves JD, Hibbitts S, Simmons G, et al. Primary human immunodeficiency virus type 2 (HIV-2) isolates infect CD4-negative cells via CCR5 and CXCR4: comparison with HIV-1 and simian immunodeficiency virus and relevance to cell tropism in vivo. J Virol 1999; 73:7795-7804. (Pubitemid 29383264)
4. Peterson K, Jallow S, Rowland-Jones SL, de Silva TI. Antiretroviral therapy for HIV-2 infection: recommendations for management in low-resource settings. Aids Res Treat 2011; 2011:463704.
5. Cavaco-Silva P, Taveira NC, Rosado L, et al. Virological and molecular demonstration of human immunodeficiency virus type 2 vertical transmission. J Virol 1998; 72:3418-3422. (Pubitemid 28175591)
6. Davis KL, Bibollet-Ruche F, Li H, et al. Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma. J Virol 2009; 83:1240-1259.
7. Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005; 49:4721-4732. (Pubitemid 41552605)
8. Repits J, Oberg M, Esbjornsson J, et al. Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency. J Gen Virol 2005; 86:2859-2869. (Pubitemid 41410478)
9. Scarlatti G, Tresoldi E, Bjorndal A, et al. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med 1997; 3:1259-1265. (Pubitemid 27508828)
10. Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther 2004; 9:57-65. (Pubitemid 38313948)
11. Melby T, Sista P, DeMasi R, et al. Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2. AIDS Res Hum Retroviruses 2006; 22:375-385. (Pubitemid 43787761)
12. Shen L, Peterson S, Sedaghat AR, et al. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med 2008; 14:762-766. (Pubitemid 351951518)
13. Sampah ME, Shen L, Jilek BL, Siliciano RF. Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance. Proc Natl Acad Sci U S A 2011; 108:7613-7618.
14. Stegmann S, Manea ME, Charpentier C, et al. Foscarnet as salvage therapy in HIV-2-infected patient with antiretroviral treatment failure. J Clin Virol 2010; 47:79-81.
15. Armstrong-James D, Stebbing J, Scourfield A, et al. Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc. Antiviral Res 2010; 86:224-226.
16. Marcelino JM, Borrego P, Rocha C, et al. Potent and broadly reactive HIV-2 neutralizing antibodies elicited by a vaccinia virus vector prime-C2V3C3 polypeptide boost immunization strategy. J Virol 2010; 84:12429-12436.
17. Blaak H, Boers PH, van der Ende ME, Schuitemaker H, Osterhaus AD. CCR5-restricted HIV type 2 variants from long-term aviremic individuals are less sensitive to inhibition by beta-chemokines than low pathogenic HIV type 1 variants. AIDS Res Hum Retroviruses 2008; 24:473-484. (Pubitemid 351457737)
18. + T cells in human immunodeficiency virus type 2 infection. J Virol 2006; 80:12425-12429.
19. Reeves JD, Gallo SA, Ahmad N, et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci U S A 2002; 99:16249-16254. (Pubitemid 35462781)
20. Poveda E, Rodes B, Toro C, Soriano V. Are fusion inhibitors active against all HIV variants? AIDS Res Hum Retroviruses 2004; 20:347-348. (Pubitemid 38429408)